<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: There is an increasing demand for accurate biomarkers for early non-invasive <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> detection </plain></SENT>
<SENT sid="1" pm="."><plain>We employed a genome-scale marker discovery method to identify and verify candidate DNA methylation biomarkers for blood-based detection of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODOLOGY/PRINCIPAL FINDINGS: We used DNA methylation data from 711 colorectal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, 53 matched adjacent-<z:mpath ids='MPATH_458'>normal</z:mpath> colonic tissue samples, 286 healthy blood samples and 4,201 tumor samples of 15 different <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types </plain></SENT>
<SENT sid="3" pm="."><plain>DNA methylation data were generated by the Illumina Infinium HumanMethylation27 and the HumanMethylation450 platforms, which determine the methylation status of 27,578 and 482,421 CpG sites respectively </plain></SENT>
<SENT sid="4" pm="."><plain>We first performed a multistep marker selection to identify candidate markers with high methylation across <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> while harboring low methylation in healthy samples and other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types </plain></SENT>
<SENT sid="5" pm="."><plain>We then used pre-therapeutic plasma and serum samples from 107 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients and 98 controls without <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, confirmed by colonoscopy, to verify candidate markers </plain></SENT>
<SENT sid="6" pm="."><plain>We selected two markers for further evaluation: methylated THBD (THBD-M) and methylated C9orf50 (C9orf50-M) </plain></SENT>
<SENT sid="7" pm="."><plain>When tested on clinical plasma and serum samples these markers outperformed carcinoembryonic antigen (CEA) serum measurement and resulted in a high sensitive and specific test performance for early <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> detection </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS/SIGNIFICANCE: Our systematic marker discovery and verification study for blood-based DNA methylation markers resulted in two novel <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> biomarkers, THBD-M and C9orf50-M </plain></SENT>
<SENT sid="9" pm="."><plain>THBD-M in particular showed promising performance in clinical samples, justifying its further optimization and clinical testing </plain></SENT>
</text></document>